This 2020 LuCE Position Paper covers data regarding access to lung cancer treatment and diagnosis, in order to raise awareness about access inequities among patients in European countries.

Data collection was undertaken using two online surveys (March until September 2019); one conducted with healthcare professionals/researchers (one or two respondents per country1) and the other conducted with pharmaceutical industry representatives (one respondent per company). Data was validated by a final consultation with patient advocates (LuCE members), lung cancer experts and pharmaceutical companies in November 2019. Supplementary desk research provided additional evidence, which strengthened our position statements.

• Download the English version
• Download the French version
• Download the Polish version